Urovant Sciences Ltd (NASDAQ:UROV)’s share price hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $14.49 and last traded at $14.06, with a volume of 1900 shares changing hands. The stock had previously closed at $13.75.
UROV has been the topic of several research reports. Zacks Investment Research raised Urovant Sciences from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research note on Tuesday, December 25th. HC Wainwright initiated coverage on Urovant Sciences in a research note on Monday, March 11th. They set a “buy” rating and a $28.00 price target on the stock. Finally, SunTrust Banks initiated coverage on Urovant Sciences in a research note on Friday. They set a “buy” rating and a $24.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Urovant Sciences has a consensus rating of “Buy” and a consensus price target of $20.29.
Urovant Sciences (NASDAQ:UROV) last issued its quarterly earnings results on Wednesday, February 13th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.22. On average, sell-side analysts forecast that Urovant Sciences Ltd will post -4.21 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of UROV. FMR LLC acquired a new position in shares of Urovant Sciences during the third quarter valued at $14,400,000. Sio Capital Management LLC acquired a new position in shares of Urovant Sciences during the third quarter valued at $7,097,000. Perceptive Advisors LLC acquired a new position in shares of Urovant Sciences during the third quarter valued at $5,552,000. BlackRock Inc. acquired a new position in shares of Urovant Sciences during the third quarter valued at $4,574,000. Finally, Citadel Advisors LLC acquired a new position in shares of Urovant Sciences during the third quarter valued at $2,209,000. 22.77% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This report was published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://transcriptdaily.com/2019/03/17/urovant-sciences-urov-reaches-new-52-week-high-at-14-49.html.
Urovant Sciences Company Profile (NASDAQ:UROV)
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Recommended Story: What is a Futures Contract?
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.